Shopping Cart 0
Cart Subtotal
USD 0

Acasti Pharma Inc (ACST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in blood lipids, and treatment and prevention of various cardiometabolic disorders. Its product include CaPre, a drug product candidate, used for the treatment of hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream; and Onemia, a medical food that is used in the dietary management of diseases associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. The company has operations in Canada. Acasti is headquartered in Laval, Quebec, Canada.

Acasti Pharma Inc (ACST)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10

Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11

Equity Offering 12

Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12

Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14

Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16

Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18

Acasti Pharma Raises USD4.35 Public Offering of Units 20

Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22

Acasti Pharma Completes Private Placement Of Units For USD 2 Million 24

Acasti Pharma Completes Public Offering Of Units For USD 23 Million 25

Acasti Pharma Completes Private Placement Of Units For USD 1 Million 27

Acasti Pharma Completes Private Placement Of Shares For USD 1 Million 28

Debt Offering 29

Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29

Acasti Pharma Inc-Key Competitors 31

Acasti Pharma Inc-Key Employees 32

Acasti Pharma Inc-Locations And Subsidiaries 33

Head Office 33

Recent Developments 34

Financial Announcements 34

Aug 14, 2018: Acasti Pharma provides business update for the first quarter of fiscal 2019 34

Jun 27, 2018: Acasti Pharma Announces Fourth Quarter And Fiscal 2018 Financial Results 36

Feb 13, 2018: Acasti Pharma Reports Third Quarter FY 2018 Financial Results 38

Aug 14, 2017: Acasti Pharma Reports First Quarter FY 2018 Financial Results 40

Jun 06, 2017: Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results 41

Jan 12, 2017: Acasti Pharma Reports Third Quarter 2017 Financial Results 43

Corporate Communications 44

Sep 24, 2018: Acasti Pharma names Jean-Francois Boily as Vice President of Finance 44

Nov 16, 2017: Acasti Pharma Announces the Election of Its Directors 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10

Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11

Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12

Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14

Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16

Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18

Acasti Pharma Raises USD4.35 Public Offering of Units 20

Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22

Acasti Pharma Completes Private Placement Of Units For USD 2 Million 24

Acasti Pharma Completes Public Offering Of Units For USD 23 Million 25

Acasti Pharma Completes Private Placement Of Units For USD 1 Million 27

Acasti Pharma Completes Private Placement Of Shares For USD 1 Million 28

Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29

Acasti Pharma Inc, Key Competitors 31

Acasti Pharma Inc, Key Employees 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Acasti Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in blood lipids, and treatment and prevention of various cardiometabolic disorders. Its product include CaPre, a drug product candidate, used for the treatment of hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream; and Onemia, a medical food that is used in the dietary management of diseases associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. The company has operations in Canada. Acasti is headquartered in Laval, Quebec, Canada.

Acasti Pharma Inc (ACST)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10

Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11

Equity Offering 12

Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12

Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14

Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16

Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18

Acasti Pharma Raises USD4.35 Public Offering of Units 20

Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22

Acasti Pharma Completes Private Placement Of Units For USD 2 Million 24

Acasti Pharma Completes Public Offering Of Units For USD 23 Million 25

Acasti Pharma Completes Private Placement Of Units For USD 1 Million 27

Acasti Pharma Completes Private Placement Of Shares For USD 1 Million 28

Debt Offering 29

Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29

Acasti Pharma Inc-Key Competitors 31

Acasti Pharma Inc-Key Employees 32

Acasti Pharma Inc-Locations And Subsidiaries 33

Head Office 33

Recent Developments 34

Financial Announcements 34

Aug 14, 2018: Acasti Pharma provides business update for the first quarter of fiscal 2019 34

Jun 27, 2018: Acasti Pharma Announces Fourth Quarter And Fiscal 2018 Financial Results 36

Feb 13, 2018: Acasti Pharma Reports Third Quarter FY 2018 Financial Results 38

Aug 14, 2017: Acasti Pharma Reports First Quarter FY 2018 Financial Results 40

Jun 06, 2017: Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results 41

Jan 12, 2017: Acasti Pharma Reports Third Quarter 2017 Financial Results 43

Corporate Communications 44

Sep 24, 2018: Acasti Pharma names Jean-Francois Boily as Vice President of Finance 44

Nov 16, 2017: Acasti Pharma Announces the Election of Its Directors 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Acasti Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Acasti Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Acasti Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Acasti Pharma to Enter into Agreement with China-Based Pharmaceutical Company 10

Xymogen Enters Into Distribution Agreement With Acasti Pharm For LipiChol540 11

Acasti Pharma Raises USD19.1 Million in Public Offering of Shares 12

Acasti Pharma Prices Marketed Public Offering of Shares for USD18.7 Million 14

Acasti Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD9 Million 16

Acasti Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD0.7 Million 18

Acasti Pharma Raises USD4.35 Public Offering of Units 20

Acasti Pharma Raises USD4.3 Million in Public Offering of Units 22

Acasti Pharma Completes Private Placement Of Units For USD 2 Million 24

Acasti Pharma Completes Public Offering Of Units For USD 23 Million 25

Acasti Pharma Completes Private Placement Of Units For USD 1 Million 27

Acasti Pharma Completes Private Placement Of Shares For USD 1 Million 28

Acasti Pharma Raises USD1.5 Million in Private Placement of 8% Debentures and Warrants Due 2020 29

Acasti Pharma Inc, Key Competitors 31

Acasti Pharma Inc, Key Employees 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Acasti Pharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.